Table 2. Characteristics of cohort studies reporting PCP occurrence in bi-weekly and tri-weekly rituximab-contained therapies.
| Author (year) | Country | Disease category | Cohort size | Diagnostic method | Regimens | No of pts in therapy | Onset time of PCP | Outcome | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| bi-weekly | tri-weekly | Cured | det | died | |||||||
| Katsuya (2009) | Japan | NHL | 129 | PCR/β-glucan | R-CHOP | 2 | 127 | 4,6,7cycle | 2 | 0 | 1 |
| Kolstad a (2007) | Norway | NHL | 55 | PCR | R-CHOEP | 46 | 9 | NG | 6 | 0 | 0 |
| Kolstad b (2007) | Norway | NHL | 46 | PCR | R-CHOP | 32 | 14 | NG | 4 | 0 | 0 |
| Hardak (2012) | Israel | DLBCL | 132 | PCR | R-CHOP | 85 | 47 | 2,5,5,6,6cycle | 0 | 3 | 2 |
det: deteriorated; DLBCL: diffuse large B cell lymphoma; NHL: non-Hodgkin’s lymphoma; NG: not given; NOS: Newcastle-Ottawa quality assessment scale; pts: patients. PCR: polymerase chain reaction; R-CHO(E)P: rituximab plus cyclophosphamide, doxorubicin, vincristine, (etoposide), prednisone